Frequency of Ceftazidime-Avibactam Susceptibility In Specimens of Carbapenem-Resistant Pseudomonas Aeruginosa In A Tertiary Care Hospital

Fatima Rubab; Inam Ullah  Khan; Rana Muhammad  Naeem; Fatima Tuz  Zahra; Mehreen  Furqan; Taiba  Ahmad

doi:10.51253/pafmj.v76i2.12332

Authors

Fatima Rubab Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan
Inam Ullah Khan Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan
Rana Muhammad Naeem Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan
Fatima Tuz Zahra Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan
Mehreen Furqan Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan
Taiba Ahmad Department of Microbiology, Combined Military Hospital Multan /National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76i2.12332

Keywords:

Carbapenem resistant Pseudomonas aeruginosa (CRPA), Ceftazidime avibactam (CAZ-AVI), Multi drug resistant (MDR)

Abstract

Objective: To determine the frequency of Ceftazidime-Avibactam (CAZ-AVI) susceptibility in specimens of Carbapenem-resistant Pseudomonas aeruginosa (CRPA) at a tertiary care hospital.

Study Design: Analytical cross-sectional study.

Place and Duration of Study: Department of Microbiology, Combined Military Hospital (CMH), Multan, Pakistan, from Jan-Jun 2024.

Methodology: Specimens of carbapenem-resistant Pseudomonas aeruginosa were included in the study to find the susceptibility of CAZ-AVI using the standard Kirby Bauer disc diffusion method. Zones were interpreted using a Vernier caliper following Clinical Standard Institute (CLSI) 2023, where zone of CAZ-AVI ≥21 was considered as susceptible.

Results: The total sample size was 103 CRPA specimens, out of which, 47(45.60%) were found to be susceptible to CAZ-AVI with an average zone of inhibition of 16.9 ± 8.8 mm, with male patients showing more susceptibility as compared to females (51.00% vs. 40.40%). The majority 44(68.80%) of resistant cases were from inpatient department as compared to the outpatient department 12(30.80%) (p-value <0.001). Organisms were more susceptible in the specimens bronchioalveolar lavage sputum (87.50% and 75.00% respectively) whereas the most resistant isolates were found in Tracheal aspirate and blood specimens (100.00%) (p-value <0.001).

Conclusion: The study demonstrates that approximately 45.60% of carbapenem‑resistant Pseudomonas aeruginosa (CRPA) isolates at a tertiary care hospital are susceptible to Ceftazidime‑Avibactam (CAZ‑AVI), supporting its potential role as a valuable treatment option.

Downloads

Download data is not yet available.

References

1. Lee YL, Ko WC, Hsueh PR. Geographic patterns of carbapenem-resistant Pseudomonas aeruginosa in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2015–2019. Antimicrob Agents Chemother 2022; 66: e0200021.

https://doi.org/10.1128/aac.02000-21

2. Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 2019; 32 : e00031-19.

https://doi.org/10.1128/CMR.00031-19

3. Mirzaei B, Bazgir ZN, Goli HR, et al. Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran. BMC Res Notes 2020; 13: 434.

https://doi.org/10.1186/s13104-020-05224-w

4. Zaragoza R, Vidal-Cortés P, Aguilar G, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care 2020; 24: 371.

https://doi.org/10.1186/s13054-020-03091-2

5. Mosley JF, Smith LL, Parke CK, et al. Ceftazidime‑avibactam (Avycaz): for the treatment of complicated intra‑abdominal and urinary tract infections. P T 2016; 41: 479–484, 489–490.

6. Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability‑adjusted life‑years caused by infections with antibiotic‑resistant bacteria in the EU and the European Economic Area in 2015: a population‑level modelling analysis. Lancet Infect Dis 2019; 19: 56–66.

https://doi.org/10.1016/S1473-3099(18)30605-4

7. Van Duin D, Arias CA, Komarow L, et al. Molecular and clinical epidemiology of carbapenem‑resistant Enterobacterales in the USA (CRACKLE‑2): a prospective cohort study. Lancet Infect Dis 2020; 20: 731–741.

https://doi.org/10.1016/S1473-3099(19)30755-8

8. Tiseo G, Brigante G, Giacobbe DR, et al. Diagnosis and management of infections caused by multidrug‑resistant bacteria: guideline endorsed by SIMIT, SITA, GISA, AMCLI and SIM. Int J Antimicrob Agents 2022; 60: 106611. https://doi.org/10.1016/j.ijantimicag.2022.106611

9. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram‑negative bacteria. Clin Infect Dis 2019; 69: S521–S528.

https://doi.org/10.1093/cid/ciz824

10. Farooq L, Memon Z, Ismail MO, et al. Frequency and antibiogram of multi‑drug resistant Pseudomonas aeruginosa in a tertiary care hospital of Pakistan. Pak J Med Sci 2019; 35: 1622–1627.

https://doi.org/10.12669/pjms.35.6.930

11. Pagani L, Mantengoli E, Migliavacca R, et al. Multifocal detection of multidrug‑resistant Pseudomonas aeruginosa producing the PER‑1 extended‑spectrum β‑lactamase in Northern Italy. J Clin Microbiol 2004; 42: 2523–2529.

https://doi.org/10.1128/JCM.42.6.2523-2529.2004

12. Özlem KO, Tığlı GA, Özen HN, et al. Evaluation of ceftazidime‑avibactam susceptibility in carbapenem‑resistant Klebsiella pneumoniae and Pseudomonas aeruginosa isolates. J Med Palliat Care 2022; 4: 625–629.

https://doi.org/10.47582/jompac.1372443

13. Pérez A, Gato E, Pérez‑Llarena J, et al. High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator‑associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother 2019; 74: 1244–1252.

https://doi.org/10.1093/jac/dkz030

14. Karlowsky JA, Kazmierczak KM, Valente ML, et al. In vitro activity of ceftazidime‑avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017–2019. Braz J Infect Dis 2021; 25: 101647.

https://doi.org/10.1016/j.bjid.2021.101647

15. Wise MG, Karlowsky JA, Hackel MA, et al. In vitro activity of ceftazidime‑avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub‑Saharan Africa: ATLAS Global Surveillance Program 2017–2021. J Glob Antimicrob Resist 2023; 35: 93–100.

https://doi.org/10.1016/j.jgar.2023.08.022

16. Sid MA, Abdel HH, Hassan AA, et al. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. J Antimicrob Chemother 2019; 74: 3497–3504.

https://doi.org/10.1093/jac/dkz379

17. Özlem KO, Tığlı GA, Özen HN, et al. Evaluation of ceftazidime‑avibactam susceptibility in carbapenem‑resistant Klebsiella pneumoniae and Pseudomonas aeruginosa isolates. J Med Palliat Care 2022; 4: 625–629.

https://doi.org/10.47582/jompac.1372443

18. Koca Ö, Tığlı GA, Özen HN, Çekin Y, Seyman D. Evaluation of ceftazidime‑avibactam susceptibility in carbapenem‑resistant Klebsiella pneumoniae and Pseudomonas aeruginosa isolates. J Med Palliat Care 2023; 4: 625–629.

https://doi.org/10.47582/jompac.1372443

19. Mirzaei B, Bazgir ZN, Goli HR, et al. Prevalence of multi‑drug resistant (MDR) and extensively drug‑resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran. BMC Res Notes 2020; 13: 434.

https://doi.org/10.1186/s13104-020-05224-w